Phase 1 Mesothelioma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed (confirmed by biopsy) with cancer that has spread to the lining of the lung (pleura), or mesothelioma, and you have fluid buildup around your lungs — and your cancer has not responded to standard treatments available for your cancer type.
- You are at least 18 years old and under 80 years old.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use an approved form of birth control (such as condoms, a diaphragm, injectable or oral contraception, or abstinence) during the trial and for at least 6 months after treatment; male participants must also use birth control from enrollment through 6 months after treatment.
- Your heart is pumping blood effectively enough, confirmed by a heart scan (a score of 45% or above).
- You do not need extra oxygen to breathe, and you do not feel breathless right after having fluid drained from around your lungs.
- You are able to carry out normal daily activities reasonably well, as measured by a standard performance score (Karnofsky score of 70 or above).
- Doctors expect you to live for more than 12 weeks.
- You are able to understand the risks and details of this trial and can give your own consent to take part.
- You agree to allow the trial team to collect information about your background and health.
Who may not be able to join:
- You have breast, kidney, lung, pancreatic, prostate, ovarian, or certain rare cancers, or melanoma.
- You have HIV with detectable levels of the virus in your blood (however, if your HIV is well controlled on medication with an undetectable viral load, you may still be considered — confirm with trial site).
- You have hepatitis B with active virus in your blood.
- You have hepatitis C with active virus in your blood.
- You are currently being treated for a bacterial, fungal, or viral infection.
- You have had a heart attack within the last 6 months, or you have significant heart disease or an uncontrolled irregular heartbeat.
- You have taken an experimental drug within 30 days before the fluid collection procedure.
- You have received chemotherapy or radiation therapy within 2 weeks before the fluid collection (note: certain immunotherapy drugs targeting immune checkpoints may still be allowed — confirm with trial site).
- You have been taking steroid medication (such as prednisone) at a dose higher than 10 mg per day within 2 weeks before the fluid collection procedure.
- You are on immune-suppressing medication that cannot safely be stopped for 4 weeks before the fluid collection, as decided by your prescribing doctor.
- Your blood test results show significant problems with your liver, kidneys, or blood counts (specific thresholds apply — confirm with trial site).
- You are pregnant or currently breastfeeding.
- You have previously had a solid organ transplant (such as a kidney, liver, or heart transplant).
- The trial team believes you may have difficulty following the trial schedule or procedures.
- You belong to a group considered vulnerable (such as being homeless, having a developmental disability, or being incarcerated), or you have any condition that prevents you from fully understanding and consenting to the trial.
- You have had a severe allergic reaction (anaphylaxis) to penicillin in the past.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Bartlett, MD, Allegheny Health Network
Phone: 412-359-3731
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device; Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device; Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device; To demonstrate the safety of intrapleural administration of the locally manufactured ACT product plus Interleukin 2 (IL-2) to study patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.